NU-LISINOPRIL TABLET

Country: Kanada

Bahasa: Inggeris

Sumber: Health Canada

Bahan aktif:

LISINOPRIL

Boleh didapati daripada:

NU-PHARM INC

Kod ATC:

C09AA03

INN (Nama Antarabangsa):

LISINOPRIL

Dos:

5MG

Borang farmaseutikal:

TABLET

Komposisi:

LISINOPRIL 5MG

Laluan pentadbiran:

ORAL

Unit dalam pakej:

30/100/500

Jenis preskripsi:

Prescription

Kawasan terapeutik:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Ringkasan produk:

Active ingredient group (AIG) number: 0121550003; AHFS:

Status kebenaran:

CANCELLED (UNRETURNED ANNUAL)

Tarikh kebenaran:

2018-03-28

Ciri produk

1
PRODUCT MONOGRAPH
PR
NU-LISINOPRIL
LISINOPRIL TABLETS USP
5, 10, 20 AND 40 MG
ANGIOTENSIN CONVERTING ENZYME INHIBITOR
NU-PHARM INC.
DATE OF PREPARATION:
50 MURAL STREET, UNITS 1 & 2
October 7, 2009
RICHMOND HILL, ONTARIO
L4B 1E4
CONTROL#: 133152
_ _
1
PRODUCT MONOGRAPH
Pr
NU-LISINOPRIL
Lisinopril Tablets USP
5, 10, 20 and 40 mg
THERAPEUTIC CLASSIFICATION
Angiotensin Converting Enzyme Inhibitor
ACTION AND CLINICAL PHARMACOLOGY
Lisinopril is an ACE inhibitor, which is used in the treatment of
hypertension, congestive heart
failure and following myocardial infarction in hemodynamicaly stable
patients.
Angiotensin converting enzyme (ACE) is a peptidyl dipeptidase which
catalyzes the conversion of
angiotensin I to the pressor substance, angiotensin II. Inhibition of
ACE results in decreased
plasma angiotensin II, which leads to increased plasma renin activity
(due to removal of negative
feedback of renin release) and decreased aldosterone secretion.
Although the latter decrease is
small, it results in a small increase in serum K+. In patients treated
with lisinopril and a thiazide
diuretic there was essentially no change in serum potassium (see
PRECAUTIONS).
ACE is identical to kininase II. Thus, lisinopril may also block the
degradation of bradykinin, a
potent vasodilator peptide. However, the role that this plays in the
therapeutic effects of NU-
LISINOPRIL is unknown.
2
While the mechanism through which lisinopril lowers blood pressure is
believed to be primarily
the suppression of the renin-angiotensin-aldosterone system lisinopril
also lowers blood pressure
in patients with low-renin hypertension.
Administration of lisinopril to patients with hypertension results in
a reduction of both supine and
standing blood pressure. Abrupt withdrawal of lisinopril has not been
associated with a rapid
increase in blood pressure. In most patients studied, after oral
administration of an individual
dose of lisinopril, the onset of antihypertensive activity is seen at
one hour with peak reduction of
blood pressure achieved by